Cetin, EyupSancak, TunahanKeles, Omer FarukUnlu, IlkerAkyol, Mehmet EdipArabacı, Ozkan2025-03-262025-03-2620231306-696X1307-794510.14744/tjtes.2023.606212-s2.0-85179357879https://doi.org/10.14744/tjtes.2023.60621https://search.trdizin.gov.tr/tr/yayin/detay/1263576https://hdl.handle.net/20.500.14704/932BACKGROUND: This experimental study was designed to investigate the histopathological and immunohistochemical effects of Shilajit in rats with experimentally induced spinal cord injury (SCI). METHODS: The rats were divided into three groups: Control group: The group in which spinal cord damage was created but no drug was administered. Low-dose group: This is the group in which intraperitoneal Shilajit is given at a dose of 150 mg/kg at the 1st h, 1st day, 2nd day, and 3rd day after spinal cord damage was induced. High-dose group: This is the group in which intraperitoneal Shilajit is given at a dose of 250 mg/kg at the 1st h, 1st day, 2nd day, and 3rd day after spinal cord damage was induced. Thin sections taken from the spinal cord after euthanasia were sent for histopathological and immunohistochemical examination. RESULTS: Histopathological examination of the high-dose group showed lower amounts of morphological findings compared to the low-dose group and control group. While a significant CD68 immune reaction was observed in the control group of rats with spinal injury, the positive immune reaction was found to be significantly decreased in the Shilajit-applied groups. CONCLUSION: It is thought that the use of Shilajit in SCI will reduce the effects of secondary damage in SCI and that its administration to such patients will have positive effects on the results.eninfo:eu-repo/semantics/openAccessExperimental study; primary injury; secondary injury; shilajit; spinal cord paralysis; spinal cord injuryArticle13341238073457Q31329126357629WOS:001125282700002Q4